Lucas Delmonico

Dr. Lucas Delmonico

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Human Pathology
Verified
Journal Article
Closed access
LDLucas Delmonico
Lucas Delmonico
AMAline dos Santos Moreira
Aline dos Santos Moreira
MFMarco Felipe Franco
Marco Felipe Franco
EEEliane Barbosa Esteves
Eliane Barbosa Esteves
LSLuciano Scherrer
Luciano Scherrer
GAGilda Alves
Gilda Alves

8 July 2016 in Oncology Letters
Verified
Journal Article
Open access
PDF file
LDLucas Delmonico
Lucas Delmonico
MBMaryah Bravo
Maryah Bravo
RSRafaele Tavares Silvestre
Rafaele Tavares Silvestre
MOMaria Helena Faria Ornellas
Maria Helena Faria Ornellas
CACarolina Maria De Azevedo
Carolina Maria De Azevedo
GAGilda Alves
Gilda Alves
The present study evaluated the proteomic profile of saliva and plasma from women with impalpable breast lesions using nano-liquid chromatography-quadrupole-time-of-flight (nLC-Q-TOF) technology. Plasma and saliva from patients with fibroadenoma (n=10), infiltrating ductal carcinoma (n=10) and healthy control groups (n=8) were assessed by combinations of inter/intra-group analyses, revealing significant quantitative and qualitative differences. The major differentially-expressed proteins in the saliva of patients compared with the controls were α2-macroglobulin and ceruloplasmin, but the proteins that met the minimum fold-change and P-value cut-offs were leukocyte elastase inhibitor and α-enolase, and deleted in malignant brain tumors 1. Concerning plasma, α-2-macroglobulin and ceruplasmin were upregulated, while other proteins such as haptoglobin, hemopexin and vitamin D-binding protein were downregulated compared with the control. The changes in immune, molecular transport and signaling pathways were the most representative in the proteomic profile of the saliva and plasma. This is the first study to describe the proteome of saliva and plasma from the same women with impalpable breast lesions.

15 March 2020 in Pakistan Journal of Biological Sciences
Verified
Journal Article
Closed access
RSRafaele Tavares Silvestre
Rafaele Tavares Silvestre
MBMaryah Bravo
Maryah Bravo
FSFabio Santiago
Fabio Santiago
LDLucas Delmonico
Lucas Delmonico
LSLuciano Scherrer
Luciano Scherrer
MOMaria Helena Ornellas
Maria Helena Ornellas
Hypermethylation in Gene Promoters Are Induced by Chronic Exposure to Benzene, Toluene, Ethylbenzene and Xylenes

31 August 2022 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
MCMariana Chantre-Justino
Mariana Chantre-Justino
GAGilda Alves
Gilda Alves
LDLucas Delmonico
Lucas Delmonico
Head and neck squamous cell carcinomas (HNSCCs) represent the most common epithelial tumors that arise from mucosa of the oral cavity, pharynx, and larynx. The development of HNSCCs is usually associated with tobacco use, alcohol consumption, and human papillomavirus (HPV) infection. Most HNSCCs are diagnosed in advanced states, leading to a worse clinical outcome. Screening tests based on potential biomarkers associated with HNSCCs could improve this scenario. Liquid biopsy has emerged as a promising area of cancer investigation, offering a minimally invasive approach to track circulating biomarkers in body fluids that could potentially contribute to the diagnosis, predict prognosis, and monitor response to treatment. This review will discuss translational studies describing the clinical applications of liquid biopsy in HPV‐negative and HPV‐positive HNSCCs focused on circulating nucleic acids [cell-free DNA (cfDNA) and cell-free RNA (cfRNA)], circulating tumor cells (CTCs), and extracellular vesicles (EVs), which can be found in plasma, serum, and saliva.

1 August 2019 in Auris Nasus Larynx
Verified
Journal Article
Closed access
MFMarcelo Cardoso Figueiredo
Marcelo Cardoso Figueiredo
MCMariana Chantre-Justino
Mariana Chantre-Justino
LDLucas Delmonico
Lucas Delmonico
RSRafaele Tavares Silvestre
Rafaele Tavares Silvestre
TCThiago Luz de Castro
Thiago Luz de Castro
MOMaria Helena Ornellas
Maria Helena Ornellas

9 August 2017 in Biomedical Reports
Verified
Journal Article
Closed access
PDF file
CLCarolina Leite
Carolina Leite
LDLucas Delmonico
Lucas Delmonico
GAGilda Alves
Gilda Alves
RGRomario José Gomes
Romario José Gomes
MMMariana Rodrigues Martino
Mariana Rodrigues Martino
MOMaria Helena Ornellas
Maria Helena Ornellas
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis, different degrees of cellular dysplasia, and increased risk of progression to acute myeloid leukemia. International Prognostic Scoring System is the gold standard for MDS classification; however, patients exhibiting different clinical behaviors often coexist in the same group, indicating that the currently available scoring systems are insufficient. The genes that have recently been identified as mutated in MDS, including additional sex combs like 1, transcriptional regulator (ASXL1), tumor protein p53 (TP53), and KRAS proto-oncogene and GTPase (KRAS)/NRAS proto-oncogene, GTPase (NRAS), may contribute to a more comprehensive classification, as well as to the prognosis and progression of the disease. In the present study, the mutations in the ASXL1, TP53 and NRAS/KRAS genes in 50 patients were evaluated by sequencing genomic bone marrow DNA. Nine patients (18%) presented with at least one type of mutation. Mutations in TP53 were the most frequent in six patients (12%), followed by ASXL1 in two patients (4%) and NRAS in one patient (2%). The nine mutations were detected in patients with low- and high-risk MDS. The screening of mutations in MDS cases contributes to the application of personalized medicine.